Yuanxiang Wang

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Venues

Journal of medicinal chemistry

Sun Yat-Sen University

Shanghai Institute of Materia Medica Chinese Academy of Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Sun Yat-Sen University Aug 01 2017

China

Associate Professor :: Sun Yat-sen University

University of Arizona Sep 01 2016 - Jul 31 2017

United States

Research Scientist :: College of Pharmacy

University of Utah Oct 01 2014 - Aug 31 2016

United States

Research Associate :: Department of Biochemistry

University of Arizona Aug 01 2012 - Oct 01 2014

United States

Research Associate :: College of Pharmacy

Education History

Shanghai Institute of Materia Medica Chinese Academy of Sciences Sep 01 2007 - Jul 31 2012

China

PHD :: Medicinal Chemistry

Publications

Wei Fang, Jianwei Zheng, Lin Deng, Yana An, Deqin Rong, Jianwei Wei, Xiao-Feng Xiong, Junjian Wang, Yuanxiang Wang
Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer. Journal of medicinal chemistry 67 (2) (2024)
Jianwei Wei, Qiongyu Shi, Bang Li, Hong Yang, Li Liu, Ruilin Zhou, Zongbo Feng, Zhenjiao Yang, Jinhong Zhan, Xiao-Feng Xiong, Xun Huang, Yuanxiang Wang
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2. Journal of medicinal chemistry (2024)
Wei Fang, Jianwei Zheng, Lin Deng, Yana An, Deqin Rong, Jianwei Wei, Xiao-Feng Xiong, Junjian Wang, Yuanxiang Wang
Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer. Journal of medicinal chemistry (2024)
Chunju Yang, Bang Li, Zongbo Feng, Huaxuan Li, Hong Yang, Zhenjiao Yang, Li Liu, Qiongyu Shi, Hong Wang, Zhong-Zhu Chen, Xun Huang, Junjian Wang, Yuanxiang Wang
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors. Journal of medicinal chemistry (2024)
Wei Fang, Jianwei Zheng, Lin Deng, Yana An, Deqin Rong, Jianwei Wei, Xiao-Feng Xiong, Junjian Wang, Yuanxiang Wang
Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer. Journal of medicinal chemistry 67 (2) (2024)
Zongbo Feng, Chunju Yang, Yi Zhang, Huaxuan Li, Wei Fang, Junhua Wang, Yichu Nie, Chang-Yun Wang, Zhi-Qing Liu, Zhimin Jiang, Junjian Wang, Yuanxiang Wang
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP. Journal of medicinal chemistry (2023)
Jiahong Zheng, Bang Li, Yingqi Wu, Xiaoshuang Wu, Yuanxiang Wang
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies. Journal of medicinal chemistry (2023)
Yi Zhang, Hong Yang, Bingbing Li, Jiayi Li, Huaxuan Li, Qiongyu Shi, Bang Li, Zekun Wang, Jiahong Zheng, Ying Zhang, Hui Dong, Xun Huang, Yuanxiang Wang
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2. Journal of medicinal chemistry (2023)
Deqin Rong, Kaixin Zhou, Wei Fang, Hong Yang, Yi Zhang, Qiongyu Shi, Yuting Huang, Jiayi Li, Hui Dong, Lanlan Li, Jian Ding, Xun Huang, Yuanxiang Wang
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5. Journal of medicinal chemistry 65 (11) (2022)
Lin Deng, Jianshan Mo, Yi Zhang, Keren Peng, Huaxuan Li, Shumin Ouyang, Zongbo Feng, Wei Fang, Jianwei Wei, Deqin Rong, Xiaolei Zhang, Yuanxiang Wang
Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3. Journal of medicinal chemistry 65 (19) (2022)
Yi Zhang, Deqin Rong, Bingbing Li, Yuanxiang Wang
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors. Journal of medicinal chemistry 64 (12) (2021)
Yuanxiang Wang, Wenhao Hu, Yanqiu Yuan
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery. Journal of medicinal chemistry 61 (21) (2018)

Yuanxiang Wang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yuanxiang Wang